14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Citigroup Upgrades Mirati Therapeutics to Buy
Citigroup analyst Yigal Nochomovitz upgrades Mirati Therapeutics (NASDAQ:MRTX) from Neutral to Buy.
Oppenheimer Downgrades Mirati Therapeutics to Perform, Lowers Price Target to $160
Oppenheimer analyst Jay Olson downgrades Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Perform and lowers the price target from $245 to $160.
Jefferies Upgrades Mirati Therapeutics to Buy, Lowers Price Target to $196
Jefferies analyst Maury Raycroft upgrades Mirati Therapeutics (NASDAQ:MRTX) from Hold to Buy and lowers the price target from $208 to $196.